For those of you looking to stall the encroaching gravitational folds, elastic creases and dynamic expression lines on your face, there’s a new solution for you. This past week, the FDA approved Jeuveau, a new wrinkle treatment for adults.

Like Botox, Jeuveau is a neurotoxin, which can be injected into crow’s feet and forehead lines to inhibit muscle contractions, thereby smoothing existing lines and also preventing the deepening of those lines over time.

According to the American Society of Plastic Surgeons, use of neurotoxin injectables has increased by 819% over the last 17 years.

Jeuveau was first put before the FDA nearly eight months ago, but the agency rejected the bid on the grounds that the treatment didn’t meet manufacturing standards — and that there were deficiencies in the original chemical composition. Since then, Evolus, the company who made the new treatment, seems to have solved these problems.

Up until now, there haven’t been very many options for people looking to smooth their fine lines. The FDA has only ever approved three neurotoxin injectables — Dysport, Xeomin, and of course, Botox, the most popular choice, which hit the market in 1989.

Since then, the demand for anti-wrinkle treatments has grown. The American Society of Plastic Surgeons noted in their most recent annual statistics that use of neurotoxin injectables has increased by 819% over the last 17 years — from a mere 786,911 procedures in 2000 to over 7.2 million in 2017.

If you’re thinking about joining those ranks and giving this brand new wrinkle treatment a try, you’re pocketbook is in luck, too: When Jeuveau hits the market, it will be nearly 25% cheaper than Botox.